Physician profile
Tracy Bourg
NPI 1871744854
$3,579.09
in general payments reported to CMS, 2019-2025
29 companies · $861 in 2025
The $861 reported for 2025 was more than what 83% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $15.69 · 2022: $806 · 2023: $639 · 2024: $1,257 · 2025: $861.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,756.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $398.69 | 2023-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Genzyme Corporation | $365.18 | 2022-2025 | |
| Lilly USA, LLC | $360.90 | 2023-2025 | Mounjaro |
| Teva Pharmaceuticals USA, INC. | $243.70 | 2023-2024 | Austedo Xr |
| Gilead Sciences, INC. | $231.72 | 2022-2024 | Epclusa |
| Janssen Pharmaceuticals, INC | $224.69 | 2024 | Spravato |
| Abbvie INC. | $202.91 | 2024-2025 | |
| Neurelis, INC. | $185.14 | 2022-2025 | Valtoco |
| Novo Nordisk INC | $160.99 | 2022-2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $158.75 | 2022-2024 | Wainua |
| Madrigal Pharmaceuticals | $146.52 | 2025 | Rezdiffra |
| Edwards Lifesciences Corporation | $125.00 | 2025 | |
| Alexion Pharmaceuticals, INC. | $108.66 | 2022 | |
| Nevro Corp. | $98.49 | 2022 | |
| Itamar Medical INC | $98.22 | 2023 | Watchpatone |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $98.06 | 2025 | |
| Exact Sciences Corporation | $92.77 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Pfizer INC. | $71.86 | 2024-2025 | |
| Sarepta Therapeutics, INC. | $23.33 | 2023 | |
| Boston Scientific Corporation | $22.52 | 2022 | |
| Myriad Genetic Laboratories, INC. | $21.39 | 2024 | Mychoice Cdx |
| Xeris Pharmaceuticals, INC. | $20.71 | 2024 | Gvoke Hypopen |
| Takeda Pharmaceuticals U.S.A., INC. | $20.39 | 2023 | |
| Phadia US INC. | $19.10 | 2025 | Immunocap |
| Seqirus USA INC | $16.44 | 2024 | Fluad, Flucelvax |
| Idorsia Pharmaceuticals US INC | $16.09 | 2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.02 | 2024 | Jardiance |
| Genentech USA, INC. | $15.69 | 2021 | |
| Tg Therapeutics, INC. | $15.16 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tracy Bourg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.